High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis
High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis have?
High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis has 221 citations in the OpenAlex counts ScholarIQ stores.
When was High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis published?
High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis has 2003 year in the ScholarIQ index.
What is the open-access status of High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis?
High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis has bronze oa status in the ScholarIQ index.
What is the DOI of High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis?
The DOI for High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis is on the source record.
What is the PMID of High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis?
The PMID for High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis is on the source record.
What is the OpenAlex record for High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis?
The OpenAlex for High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis is on the source record.